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were smokers compared with healthy controls, whereas less 
PH women were ever active smokers. However, 50% of the 
non-smoking PH women were exposed to secondhand 
smoke, leading to a significantly higher number of tobacco 
smoke-exposed individuals compared to healthy controls. 
PH smokers were significantly younger compared to those 
not exposed.  Conclusion: Active and environmental tobac-
co smoke exposure is common in PH. The higher prevalence 
of male PH smokers, the higher exposure to environmental 
tobacco smoke in PH women compared to healthy controls 
and the lower age at PH diagnosis in smokers may indicate 
a pathogenic role of tobacco smoke exposure in PH. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Precapillary pulmonary hypertension (PH) has been 
defined as a mean pulmonary artery pressure (mPAP) 
 ≥ 25 mm Hg along with a pulmonary artery wedge pres-
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 Abstract 
 Background: Animal studies and data from a single-center 
study suggest that tobacco smoke exposure may be a risk 
factor for precapillary pulmonary hypertension (PH).  Objec-
tive: We aimed to survey tobacco smoke exposure in a large 
PH collective and to compare it with epidemiological data 
from healthy subjects.  Methods: This is an international, 
multicenter, case-control study including patients with pul-
monary arterial and chronic thromboembolic PH. All pa-
tients were asked specific questions about tobacco smoke 
exposure. Healthy controls were retrieved from the Swiss 
Health Survey (n = 18,747).  Results: Overall (n = 472), 49% of 
PH patients were smokers and there was a clear sex differ-
ence (women 37%, men 71%). Significantly more PH men 
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sure  ≤ 15 mm Hg (to differentiate from pulmonary ve-
nous hypertension due to left heart disease). PH is either 
idiopathic or associated with many different disorders, 
such as collagen vascular disease, portal hypertension, 
hypoxemic lung diseases, chronic thromboembolism and 
many more  [1] . The pathophysiology of PH is still incom-
pletely understood. It is thought that excessive vasocon-
striction possibly in combination with inflammation may 
lead to endothelial dysfunction, which impairs the pro-
duction of vasodilators along with an overexpression of 
vasoconstrictors  [2] . This imbalance towards vasocon-
striction further promotes vascular remodeling. The ini-
tial harmful stimulus leading to this deleterious process 
of endothelial dysfunction and vascular remodeling in 
PH is still incompletely understood. Possible factors are 
inflammation, some forms of infection and hypoxia, all 
most probably on a genetic background of increased sus-
ceptibility and aggravated by hitherto unknown environ-
mental risk factors  [3] . The penetrance of PH in families 
with a mutation of the bone morphogenetic protein type 
II receptor is low and the mutation is seldom found in 
other forms of PH. Thus, in addition to a genetic predis-
position and associated disease, environmental factors 
may play a pathogenic role. Animal studies have shown 
that tobacco smoke exposure can lead to pulmonary en-
dothelial dysfunction and plexogenic PH  [4, 5] , and some 
reports indicate that this might also be the case in humans 
 [6, 7] . In a single-center study, we recently showed a high-
er prevalence of smokers (former or current) in patients 
with pulmonary arterial hypertension (PAH) compared 
to chronic thromboembolic PH (CTEPH) and healthy 
controls from the Swiss Health Survey (SHS) 2007  [8] . 
The present investigation aimed to extend these findings 
to PH patients in Austria and Germany.
 Patients and Methods 
 This is an international, multicenter, observational, case-con-
trol study performed in seven referral centers for PH in Europe. 
From November 2008 to October 2012, during hospital visits or by 
telephone calls, patients with precapillary PH were systematically 
asked questions about their smoking exposure and habits. Patients 
were divided into smokers (who ever smoked more than 1 packet 
of cigarettes for over 1 year,  ≥ 1 PY), current smokers and non-
smokers. Non-smokers were additionally divided into passive 
smokers (defined as having been exposed to secondhand smoke 
for >1 h a day >1 year) and not exposed. Diagnosis of precapillary 
PH was made according to international criteria and guidelines by 
a thorough investigation, including right heart catheterization, 
computed tomography of the chest, a ventilation-perfusion scan, 
a pulmonary function test, blood gases, blood values and other ex-
ams as appropriate  [1, 9] . Inclusion criteria were pulmonary artery 
pressure  ≥ 25 mm Hg and pulmonary artery wedge pressure  ≤ 15 
mm Hg. Patients with concomitant chronic lung diseases (WHO 
group III) and other relevant comorbidities (WHO group V) were 
excluded from the analysis. Some of the patients recruited in Zu-
rich participated in a first comparable study  [8] ; they were re-asked 
during follow-up visits and their data re-analyzed by a different 
team during the present survey. In addition to tobacco exposure, 
PH classification and clinical and hemodynamic data were noted 
and analyzed.
 As a control group we used data from 18,747 presumably 
healthy participants of the SHS performed in 2007. Data retrieval 
for this survey was by telephone call  [8] .
 Statistical Analysis 
 The comparison of prevalence rates of smoking exposure be-
tween our study population and the controls was performed using 
the χ 2 test. Quantitative variable differences in patients and disease 
characteristics were compared using the Mann-Whitney U test. 
Smoking exposure differences in subgroups of the study popula-
tions were calculated by the χ 2 test.
 Ethics 
 All patients gave their written informed consent to register 
their data for scientific purposes and the study was approved by 
the local ethical authorities of each participating center. It was also 
registered at ClinicalTrials.gov (NCT01484899).
 Results 
 Patients 
 Data of 533 precapillary PH patients (62% women, 
mean age 62 ± 14 years) from Switzerland (42%), Ger-
many (52%) and Austria (6%) were prospectively en-
rolled. The majority of patients were classified as PAH 
(64%), from which 60% were idiopathic and 40% were 
associated PAH. CTEPH was found in 24% of cases. A 
minority of cases had severe PH associated with chronic 
lung disease or miscellaneous (8 and 3%, respectively) 
and were excluded from further analysis due to the known 
association between tobacco smoke exposure and chron-
ic lung diseases and unknown pathogenesis in miscella-
neous forms. The patient characteristics of the 472 pa-
tients with PAH or CTEPH are summarized in  table 1 .
 Overall Tobacco Smoke Exposure by Gender 
 Of these 472 patients with PAH and CTEPH, 233 
(49%) were smokers and they demonstrated a clear sex 
difference (37% of women, 71% of men, p < 0.00001;  ta-
ble 2 ). Fifty-two (11%) PH patients were persistent smok-
ers (9% of women, 15% of men, p = 0.06). Patients started 
smoking at an average age of 20 ± 6 years (women 19 ± 4, 
men 20 ± 8, p = 0.63) and stopped with 43 ± 14 years 
(women 39 ± 14, men 47 ± 13, p = 0.0001). On average, 
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PH smokers smoked 22 ± 20 PY (males 28 ± 22, females 
16 ± 16, p < 0.0001).
 From the 239 included PH patients who were not ac-
tive smokers, 114 (48%) were exposed to secondhand 
smoke (50% of women, 40% of men, p = 0.22) for an av-
erage time of 19 ± 13 years (women 20 ± 12, men 19 ± 17, 
p = 0.32). Thus, 74% of the PH collective had ever been 
exposed to tobacco smoke, 49% were active smokers and 
24% were exposed to secondhand smoke.
 Comparison to Healthy Controls 
 In comparison to healthy controls, smokers were less 
frequently found among PH women (37 vs. 43%, p = 
0.042) but more frequently found among PH men (71 vs. 
57%, p = 0.0007;  table 2 ). Both PH women and men were 
significantly less persistent smokers compared to the 
healthy controls (women 9 vs. 24%, p < 0.0001; men 15 
vs. 32%, p < 0.0001). However, PH women and men were 
significantly more frequently exposed to secondhand 
smoke (women 50 vs. 14%, p < 0.0001; men 40 vs. 27%,
p < 0.0001), resulting in a higher overall exposure to to-
bacco smoke in PH compared with controls (women 68 
vs. 51%, p < 0.0001; men 82 vs. 69%, p = 0.0002).
 Differential Tobacco Smoke Exposure for
PAH and CTEPH 
 The prevalence of tobacco smoke exposure for PAH 
and CTEPH is shown in  table 3 . For both sexes, the per-
centage of smokers was higher in PAH compared with 
CTEPH (women 40 vs. 29%, men 75 vs. 64%), but the dif-
ferences were statistically not significant. A significantly 
higher percentage of female smokers compared to CTEPH 
women could only be detected in the group of associated 
PAH (p = 0.0447).
 No significant differences in secondhand smoke expo-
sure were found between non-smoking CTEPH and PAH 
patients, neither in men nor in women. The age of quit-
ting smoking in PAH women was significantly higher 
compared to CTEPH women (41 ± 15 vs. 33 ± 11 years,
p = 0.0267), whereas in men there was no difference be-
tween these groups. CTEPH women were significantly 
younger at diagnosis of PH than PAH women (45 ± 11 vs. 
54 ± 13 years, p = 0.001).
 PAH men showed a significantly longer total exposure 
to tobacco smoke compared to CTEPH men when taking 
active smoking calculated as cumulative pack years and 
the duration of passive tobacco smoke exposure together 
(36 ± 25 vs. 25 ± 21 PY, p = 0.0073). Overall, there seems 
be a stronger association between tobacco smoke expo-
sure and PAH than CTEPH since the incidence of male 
smokers in PAH is significantly higher, the incidence of 
environmental smoke exposure in PAH women is higher, 
and there seems to be a trend toward a higher incidence 
of female smokers in PAH compared to CTEPH.
 Differential Characteristics for Smokers and
Non-Smokers 
 Smokers among PH women and men were significant-
ly younger compared to those not exposed (women 52 ± 
13 vs. 58 ± 18 years, p = 0.0051; men 57 ± 15 vs. 64 ± 17 
years, p = 0.0288). Women who smoked were significant-
ly younger at diagnosis than men who smoked (p = 
0.0062). Detailed differential characteristics are listed in 
 table 4 .
 Female smokers had a higher right atrial pressure, and 
lower mixed venous oxygen saturation and forced expira-
tory volume in 1 s/forced vital capacity (FEV 1 /FVC) ratio, 
and males had a lower diffusion capacity for carbon mon-
oxide compared to those not exposed. Women exposed 
to secondhand smoke had a lower FEV 1 /FVC compared 
 Table 1.  Patient characteristics
Patients, n 
Female patients, n
472
301
Age at diagnosis, years 57 ± 16
BMI 26.9 ± 5.6
PH class
PH group I 342 (72)
Idiopathic 204 (43)
Associated 138 (29)
PH group IV 130 (28)
WHO functional class 
Class I + II 84 (21)
Class III 257 (63)
Class IV 65 (16)
6MWD, m 373 ± 118
Echocardiographic LV ejection fraction, % 62 ± 8
Tricuspid pressure gradient, mm Hg 65 ± 20
mPAP, mm Hg 46 ± 1
Pulmonary artery occlusion pressure, mm Hg 9.5 ± 4.6
Pulmonary vascular resistance, Wood units 9.84 ± 5.34
Cardiac index, l/min/m2 2.4 ± 0.7
Mixed venous oxygen saturation, % 62 ± 10
Arterial oxygen saturation, % 91 ± 5
FEV1, % predicted 83 ± 19
FVC, % predicted 88 ± 21
FEV1/FVC 78 ± 11
DLCO, % predicted 62 ± 21
 Data are presented as the mean ± SD, or number with percent-
age in parentheses. 6MWD = 6-Min walking distance; LV = left 
ventricular.
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to non-exposed PH women. Secondhand smoke expo-
sure in men was significantly associated with a lower 
mixed venous oxygen saturation compared to those not 
exposed.
 Discussion 
 To our knowledge, this is the first major, international, 
multicenter prospective survey on tobacco smoke expo-
sure in patients with PAH and CTEPH living in three Eu-
ropean countries. The main findings of this multicenter 
study are that overall about half of PH patients were 
smokers, with a clear sex difference of 37% of female and 
71% of male smokers. Significantly more PH men were 
smokers compared with healthy men, whereas less PH 
women were ever active smokers compared to their 
healthy counterparts. However, 50% of the non-smoking 
PH women were exposed to secondhand smoke, leading 
to an overall number of tobacco smoke-exposed individ-
uals, either as active smokers or through environmental 
tobacco smoke exposure, which was significantly higher 
compared to healthy controls  [10] . PH smokers were sig-
nificantly younger compared to the non-exposed, and fe-
male PH smokers, even though smoking less pack years, 
were significantly younger than male PH smokers. PAH 
men showed a significantly higher cumulative tobacco 
smoke exposure, taking active smoking and environmen-
tal smoke exposure together, than CTEPH men.
 Since the 1960s it has been known from animal exper-
iments that tobacco smoke inhalation leads to immediate 
and temporary elevation of the pulmonary arterial pres-
sure. This has been shown in dogs, frogs, rabbits, cats, rats 
and guinea pigs  [11] , and animal models of guinea pigs 
and rats exposed to tobacco smoke were used to study PH 
and the vasoproliferative response  [12, 13] . Our findings 
of a significantly higher smoking prevalence in PH men 
and significantly more PH women exposed to tobacco 
smoke (either active smokers or environmental expo-
sure) may point towards a possible noxious effect of to-
bacco smoke constituents on the pulmonary vasculature 
in human beings as well. These noxious stimuli in com-
bination or accumulation with other hits may contribute 
to pulmonary vasoproliferation and, ultimately, PH. In 
animal models it could be shown that tobacco smoke in-
halation leads to an early elevation of pulmonary arterial 
pressure, long before destruction of the lung parenchyma 
 [12] . This could also be demonstrated in human studies 
 [7, 14, 15] . Tobacco smoke exposure also induced cell 
proliferation of smooth muscle cells of the vasculature 
 [13, 16] , led to infiltration of inflammatory cells, and gene 
expression with overproduction of different mediators 
responsible for cell proliferation and vasomotor regula-
tion, namely inducible nitric oxide synthase  [17] , endo-
 Table 2.  Prevalence and quantity of tobacco smoke exposure
Tobacco exposure Women Men
PH control PH  control
overall
(n = 301)
odds 
ratio
CH
(n = 117)
DE
(n = 169)
SHS
(n = 10,331)
overall
(n = 1719)
odds 
ratio
CH
(n = 73)
DE
(n = 89)
SH S
(n = 8,416)
Smokers, n 112 (37)b, c 0.78c
0.24a
45 (38)b 59 (35)b, c 4,451 (43) 121 (71)b, d 1.38c
4.08a
56 (77)b, c 61 (69)b, c 4,873 (57)
Persistent smokers, n 27 (9)d 0.32c
0.58a
11 (9)d 16 (9)d 2,433 (24) 25 (15)d 0.37c
1.74a
10 (14)c 14 (16)c 2,658 (32)
Total pack years 16 ± 16b 19 ± 17a 16 ± 15a – 28 ± 22b 30 ± 24a 27 ± 20a –
Smoking start age, years 19 ± 4 20 ± 3 19 ± 5 – 20 ± 8 21 ± 7 19 ± 7 –
Smoking stop age, years 39 ± 14b 41 ± 15a 38 ± 14a – 47 ± 13b 48 ± 15a 46 ± 13a –
Age at PH diagnosis, years 56 ± 16 54 ± 17 58 ± 15 – 59 ± 16 57 ± 17 60 ± 15 –
Passive smokers 94 [50]d 8.20c
1.48a
38 [53]d 52 [47]d 801 [14] 20 [40]d 3.09c
0.67a
7 [41]c 9 [32]c 942 [27]
Exposure to secondhand smoke,
years 20 ± 12 20 ± 13 19 ± 11 – 19 ± 17 17 ± 18 16 ± 8 –
Overall active and passive 
tobacco smoke exposure, years
206 (68)b, d 2.10c
0.46a
83 (71)a, d 111 (66)a, d 5,252 (51) 141 (82)b, d 2.10c
2.17a
63 (86)a, c 70 (79)a 5,815 (69)
 Data are presented as the mean ± SD, or number with percentages in parentheses; values in square brackets are percentages of non-smokers. CH =
Switzerland; DE = Germany. Difference between genders: a p < 0.05, b p < 0.001. Difference to Swiss control group SHS: c p < 0.05, d p < 0.001. 
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thelin  [4] , vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF) and others  [18] . 
The alterations lead to endothelial dysfunction of the pul-
monary vasculature  [19] . In PAH patients, similar in-
flammatory processes with disturbances in endothelial 
and smooth muscle cell function, overexpression of 
growth factors (PDGF, VEGF, fibroblast growth factor) 
and an unbalance in vasodilators and vasoconstrictors 
(endothelin 1, serotonin, thromboxane A2, nitric oxide, 
prostacyclin) are prominent.
 We are well aware that translation of evidence based 
on animal experiments into human pathophysiology is 
more than complicated. Nevertheless, there already exists 
some evidence resulting from human studies that support 
a noxious role of tobacco smoke exposure in the human 
vasculature that is comparable to animal models: in new-
borns suffering from persistent PH, high levels of coti-
nine as a marker of maternal tobacco smoke exposure 
could be measured  [20] . Impaired vessel structure and 
function, inflammatory infiltrates with CD8+ T lympho-
cytes, vascular muscular hyperplasia and intimal thicken-
ing has been reported in patients with PH and chronic 
obstructive pulmonary disease (COPD)  [7, 15] . In smok-
ers, expression of endothelial nitric oxide synthase is re-
duced and the pulmonary vasculature shows endothelial 
dysfunction  [6] .
 In the present study we found a high prevalence of en-
vironmental smoke-exposed PH women. The adverse 
health effects of environmental smoke exposure are well 
known. An increase in inflammatory markers such as 
 L-1β, IL-4, TNF-α, white blood cell count, C-reactive 
 protein, homocysteine, fibrinogen, as well as leukocyte 
counts accompanied by an immune cell activation has 
been shown  [21, 22] . Besides this, a greater decline in lung 
function, elevated risk of cardiovascular mortality and in-
duction of growth factors (connective tissue growth fac-
tor, TGF-β, PDGF-A and B) are also known  [23, 24] . 
Whether some reactions to inhalation of environmental 
tobacco smoke or tobacco smoke in general triggers vas-
cular remodeling, similar to that seen in vasoproliferative 
PAH, is speculative and should be interpreted with cau-
tion. Our findings of a higher prevalence of secondhand 
smoke-exposed PH women and the higher prevalence of 
overall tobacco smoke exposure (smokers and passive 
smokers) compared to healthy controls might point to-
wards a noxious role of tobacco smoke on the pulmonary 
vasculature.
 It may well be that there exists a sex difference in terms 
of a greater susceptibility of women who are exposed to 
tobacco smoke compared with men. Similar sex differ- Ta
b
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ences to tobacco smoke exposure have been shown for 
lung cancer  [25] . A higher susceptibility could perhaps 
explain the lower active but higher secondhand smoke 
exposure in PH women. If predisposed women, for ex-
ample those who are genetically more susceptible due to 
alterations in genes responsible for PAH, such as BMPR-
2 mutations, are exposed to constituents of tobacco 
smoke, a lower cumulative dose might be sufficient to ini-
tiate pulmonary vascular remodeling, ultimately leading 
to PH. Potential sex differences in COPD are discussed in 
the literature  [26–28] , and it could be shown that PH is 
more frequent in female COPD patients  [29] .
 In a well-designed recent study, a possible PAH phe-
notype was characterized which showed worse exercise 
performance and survival  [30] . Characteristics of that 
phenotype are low diffusing capacity for carbon monox-
ide (D LCO ; <45%), male gender, higher tobacco smoke 
exposure and slightly lower lung function in terms of 
FEV 1 , FEV 1 /FVC and total lung capacity. No correlation 
to hemodynamic status was seen. Our data is in line with 
these findings since we found that PH was associated with 
tobacco smoke exposure in a relevant proportion of pa-
tients and we also found slightly lower than predicted 
lung function values in our collective. However, in con-
trast, the mean diffusion capacity was not severely re-
duced in our patients (mean D LCO 62%, 49–77) com-
pared with the depicted subgroup by Trip et al.  [30] with 
a D LCO <45%.
 The present study has the following limitations. First, 
we cannot exclude a selection bias. Although all centers 
systematically included consecutive PH patients, we can-
not exclude that some PH patients were missing in the 
present analysis due to logistics or for time reasons. Sec-
ond, as this survey was based on questions regarding to-
bacco smoke exposure, patients may not have remem-
bered every detail of the amount and timely sequence of 
tobacco smoke exposure, resulting in a declaration bias of 
smoking history or exposure to environmental tobacco 
smoke. However, a similar declaration bias might be 
found in the healthy controls. We cannot exclude that 
sick individuals search for a causal explanation for their 
illness and, thus, their reported smoke exposure might be 
exaggerated. Third, the mean lung volumes in the present 
cohort were relatively low (FEV 1 83 ± 19 and FVC 88 ± 
21%) and one could speculate about underlying structur-
al lung disease. However, low lung volumes have been 
shown for different PH collectives, some with concomi-
tant dynamic hyperinflation mechanical constraints  [31, 
32] . One could also argue that, consistent with the animal 
experiments, in some patients after a short exposure time 
 Table 4.  Differential characteristics of smokers, passive smokers and non-smokers
Characteristic Women  Men
smokers
(n = 112)
passive smokers
(n = 94)
not exposed
(n = 95)
smok ers
(n = 121)
passive smokers
(n = 20)
not exposed
(n = 30)
Age at diagnosis, years 52 ± 13a–c 60 ± 16 58 ± 18 57 ± 15a,c 59 ± 17 64 ± 17
WHO functional class
1 + 2
3
4
16 (16)
66 (66)
18 (18)
16 (20)
54 (66)
12 (15)
18 (22)
52 (63)
13 (16)
28 (26)
61 (57)
18 (17)
3 (25)
7 (58)
2 (17)
3 (14)
17 (77)
2 (9)
6MWD, m 359 ± 121 353 ± 111a 369 ± 110 391 ± 123 433 ± 86a 387 ± 132
Heart rate, bpm 80 ± 13a 78 ± 12 81 ± 15a 77 ± 13a 80 ± 16 72 ± 13a
Mean systemic arterial pressure, mm Hg 95 ± 14 95 ± 17 92 ± 18 92 ± 15 97 ± 14 98 ± 15
mPAP, mm Hg 47 ± 13 44 ± 14 46 ± 15 46 ± 12 44 ± 13 46 ± 16
Pulmonary vascular resistance, Wood units 10.2 ± 5.7 9.7 ± 5.9 10.9 ± 5.2 9.3 ± 5.1 8.9 ± 3.9 8.7 ± 4.1
Right atrial pressure, mm Hg 8.5 ± 5.2c 7.6 ± 4.9 6.7 ± 4.7a 8.1 ± 5.0 7.8 ± 5.3 9.3 ± 5.1a
Arterial oxygen saturation, % 92.0 ± 4.3 91.1 ± 7.7 92.2 ± 4.1 90.8 ± 5.8 90.3 ± 4.6 92.1 ± 5.3
Arterial oxygen tension, kPa 8.5 ± 1.5 8.8 ± 2.2 8.7 ± 1.8 8.5 ± 1.6 8.3 ± 1.9 8.8 ± 1.8
Mixed venous oxygen saturation, % 61 ± 10b, c 65 ± 10a 65 ± 9 61 ± 9 59 ± 9a, c 64 ± 7
FEV1, % 82 ± 17 84 ± 20 87 ± 20 80 ± 19 79 ± 18 82 ± 21
FEV1/FVC 77 ± 9c 78 ± 11c 81 ± 11a 76 ± 12 74 ± 13 77 ± 11a
DLCO, % 62 ± 19 66 ± 21 61 ± 19 60 ± 22c 65 ± 25 68 ± 23
 Data are presented as the mean ± SD, or number with percentages in parentheses. 6MWD = 6-Min walking distance. Difference between genders:
a p < 0.05. Difference to passive smokers: b p < 0.05. Difference to not exposed: c p < 0.05. 
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tobacco smoke exposition leads to changes in the pulmo-
nary vasculature before noticeable destruction of the lung 
parenchyma, without a progressive increase in pulmo-
nary arterial pressures even after lung destruction be-
comes manifest  [12] . With half of PH patients being 
smokers, some might have intrinsically smoke-related 
lung disease with alterations in the pulmonary vessels but 
not yet in the airways. The fact that PH in COPD charac-
teristically shows mild elevations in pulmonary arterial 
pressures usually not exceeding 30–35 mm Hg  [33, 34] 
and that in our study 82% of all smokers showed a high 
mPAP of >35 mm Hg strongly discourages airway disease 
as being the major cause of PH in our collective. Further-
more, it has to be mentioned that our study includes in-
cident and prevalent cases that cause a lead time bias. In-
cident cases, presumably showing a phenotype with worse 
prognosis, may have already disappeared by the time of 
conducting the study, creating an overweight of prevalent 
cases with better prognosis and weaker association or 
sensibility to tobacco smoke as the offending agent.
 In summary, we could herein show that a history of ac-
tive or environmental tobacco smoke exposure is highly 
prevalent in PH patients. Supported by experimental data 
from animal models and evidence of inflammation and 
endothelial dysfunction in humans as a response to tobac-
co smoke exposure, these data may indicate that tobacco 
smoke and its constituents are, among various other fac-
tors, involved in the pathogenesis of human PH, perhaps 
in terms of a second hit to genetically susceptible individu-
als. These findings are important for PH patients and their 
caregivers, as early counselling and protection may pre-
vent disease manifestation in relatives or patients at risk.
 Conclusion 
 Tobacco smoke exposure is common in PH: over one 
third of PH women and two thirds of PH men were active 
smokers. Strikingly, 10–15% of PH patients are persistent 
smokers and half of the non-smoking PH women were 
exposed to secondhand smoke. The higher prevalence of 
male PH smokers, the significantly higher exposure to en-
vironmental tobacco smoke in PH women compared to 
healthy subjects, and the lower age at PH diagnosis in 
smokers may indicate that tobacco smoke exposure dete-
riorates PH, that it might be involved as a second hit in 
the pathogenesis of PH, and that women may be more 
susceptible to the constituents of tobacco smoke.
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